Seattle Genetics, Inc. (NASDAQ:SGEN) Director Bros. Advisors Lp Baker bought 3,846,153 shares of the stock in a transaction on Thursday, February 1st. The stock was purchased at an average price of $52.00 per share, for a total transaction of $199,999,956.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.
Seattle Genetics, Inc. (SGEN) traded down $2.63 on Monday, hitting $53.27. The stock had a trading volume of 2,642,882 shares, compared to its average volume of 1,305,333. The company has a market cap of $7,980.00, a P/E ratio of -61.23 and a beta of 2.08. Seattle Genetics, Inc. has a 52 week low of $45.31 and a 52 week high of $71.32.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP boosted its stake in shares of Seattle Genetics by 116.5% during the 3rd quarter. Quantbot Technologies LP now owns 2,654 shares of the biotechnology company’s stock worth $144,000 after acquiring an additional 1,428 shares in the last quarter. Bristlecone Advisors LLC bought a new stake in Seattle Genetics during the 3rd quarter valued at approximately $180,000. Virtu Financial LLC bought a new stake in Seattle Genetics during the 3rd quarter valued at approximately $203,000. DRW Securities LLC bought a new stake in Seattle Genetics during the 2nd quarter valued at approximately $207,000. Finally, Caisse DE Depot ET Placement DU Quebec bought a new stake in Seattle Genetics during the 3rd quarter valued at approximately $208,000. Institutional investors own 98.92% of the company’s stock.
SGEN has been the topic of a number of recent research reports. Cann initiated coverage on Seattle Genetics in a research note on Wednesday, November 8th. They issued a “hold” rating on the stock. Oppenheimer restated a “hold” rating on shares of Seattle Genetics in a research note on Thursday, December 7th. Guggenheim restated a “buy” rating and issued a $72.00 target price on shares of Seattle Genetics in a research note on Monday, October 23rd. BidaskClub upgraded Seattle Genetics from a “sell” rating to a “hold” rating in a research note on Saturday, December 9th. Finally, TheStreet upgraded Seattle Genetics from a “d” rating to a “c” rating in a research note on Thursday, November 16th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $63.76.
TRADEMARK VIOLATION NOTICE: This article was first reported by Stock Observer and is the property of of Stock Observer. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.thestockobserver.com/2018/02/05/bros-advisors-lp-baker-buys-3846153-shares-of-seattle-genetics-inc-sgen-stock.html.
About Seattle Genetics
Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).
Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.